Topadur Pharma AG

Topadur Pharma AG is attending BIO-Europe in Stockholm, Sweden, November 4-6, 2024. Dr. Reto Naef, Chairman & CEO a.i. and PD Dr. Matthias Schäfer, Chief Innovation Officer of Topadur are excited for some dynamic discussions on financial and strategic partnerships. #Topadur #Innovation #BIOEurope #Stockholm #strategicpartnerships

Topadur Pharma AG is delighted to announce the appointments of PD Dr. Matthias Schäfer as Chief Innovation Officer (CIO) and Prof. Dr. Jay S. Siegel as Chief Research Officer (CRO). “I’m excited to announce Matthias Schäfer and Jay Siegel's appointment. Together, they bring profound knowledge and sound experience in business development within healthcare. Matthias and Jay will significantly strengthen our team, adding complementary expertise.” stated Pascal Brenneisen, CEO Topadur Pharma AG. For more information, check out the press release on the Topadur website with the following link, https://lnkd.in/e6w_eUys Topadur team welcomes Matthias and Jay and look forward to working with them towards IPO journey. #Topadur #Innovation

Today, on #WorldSclerodermaDay 2024, Topadur Pharma AG stands with the 2.5 million people worldwide affected by this rare autoimmune disorder. Systemic sclerosis (SSc) and its complications, like digital ulcers and Raynaud’s phenomenon, can severely impact patients' daily lives. At Topadur, we're committed to making a difference: 🔬 Our lead candidate, TOP-N53, is advancing to a Phase 2a clinical trial for digital ulcers in SSc patients. This trial is part of an Innosuisse-funded Start-up Innovation Project. 🤝 We're collaborating with field experts to bring hope to those affected by SSc. Follow us for updates on this exciting journey as we work towards innovative solutions for SSc patients. #Scleroderma #RareDiseaseResearch #ClinicalTrials #BiotechInnovation #TOPN53 #Topadur

Team Topadur had an exciting time in South Korea!!! 😀 Jaan Strang and Tobias Braun from Topadur Pharma AG visited our collaborators at Yonsei University and Juvic Inc. in the context of our transnational Innosuisse project. They had dynamic interactions with the South Korean partners. The core focus of the visit was coordinating project activities and discussions regarding project plans, knowledge transfer, and harmonization for improved disease management in Raynaud’s phenomenon in Systemic sclerosis. During the visit, our partners shared the latest developments in their microneedle technology to the extent that we could test their first marketed product, Needeep. This visit strengthened our collaboration even further! We look forward to new developments in this project. #Topadur #Yonsei #Juvic #startup #TOPN53 

Topadur Pharma AG is delighted to announce that we have signed a partnering and licensing agreement with Oshen Bio. This binding agreement is to develop the liquid topical formulation of TOP-M119 for treating Alopecia. We are excited for the upcoming developments in this journey. "Based on our pre-clinical data, we are convinced that TOP-M119 can become a game changer in treating hair loss and improving hair quality. The partnering agreement with Oshen helps to speed up the development and provide faster access to patients,” said Pascal Brenneisen, CEO of Topadur Pharma AG. #Topadur #Oshenbio #Alopecia #TOPM119 #innovation #startup #scaleup

Topadur Pharma AG with Reto Naef, Pascal Brenneisen, and Christian Ludin, is attending the Swiss Biotech Day 2024 in Basel. 🚀Panel discussion – Maintaining Funding Flexibility by KPMG Switzerland 📍Marriott Hotel (Monday, April 22, 2024 / 15:30 - 16:15) Our Founder and Chairman, Dr. Reto Naef, joins the panel to discuss whether a public listing is the best way to create value and what paths a late-stage biotech company can consider. Join them to discuss the opportunities and challenges of an IPO and exchange experiences in the Swiss biotech ecosystem.   🎤Topadur – Clinical stage biotech company presentation 📍Room Sydney (Tuesday, April 23, 2024 / 14:45 - 15:00) Dr. Reto Naef is excited to talk about the latest developments in our portfolio, ranging from ongoing discovery to clinical development.   #Swissbiotechday #Topadur Swiss Biotech Association

Today, on World Health Day, the World Health Organization highlights that health is a fundamental human right with the theme "My health, my right". Topadur Pharma AG is proud to highlight its continuous efforts for health betterment and accessibility with our novel drug candidates for diseases with unmet medical needs. With our innovative approach, we aspire to exploit the potential of the NO/cGMP signaling pathway to repair gene expression and regulate microcirculation in several diseases. Topadur focuses on disruptive therapies for Wound Healing, Skin Fibrosis, Ophthalmology, Medical Cosmetics (Alopecia, Skin Aging), Oncology & Lung Fibrosis.   Our commitment to health innovation is driven by a mission: to improve patient life globally. Discover more about our research and development and the potential of NO/cGMP modulation at our website www.topadur.com. #WorldHealthDay #MyHealthMyRight #Innovation #Topadur

Team Topadur is currently in Barcelona attending #BioEuropeSpring. Connect with them for dynamic interactions on strategic partnerships.  Topadur Pharma AG #Topadur #SwissBiotech 

Topadur Pharma AG is attending BIO-Europe Spring in Barcelona March 18–20, 2024. Join us at the premier springtime partnering event #BioEuropeSpring https://lnkd.in/dXrgQP6G. Reto Naef- our Chairman and Founder, Pascal Brenneisen- our CEO and Fiona Gao are excited for some dynamic discussions on financial and strategic partnerships.  

A special post by Topadur Pharma AG for the Raynaud's awareness month